Ask the Expert: Which Non-Genomic Biomarkers Are Most Useful for Monitoring Patients After Initial Treatment?

Posted by Alan W. Partin, MD, PhD | Oct 2017

Alan W. Partin, MD, Johns Hopkins Medical Institutions, Baltimore, Maryland, discusses which non-genomic biomarkers are the most useful for monitoring patients after initial treatment.

Interview produced by Prostatepedia

Keywords: non-genomic biomarkers, PSA test, prostate cancer

About The Author

Alan W. Partin, MD, PhD

Dr. Partin is the Jakurski Family Director and Professor of Urology at Johns Hopkins in Baltimore, Maryland. He is the author or co-author of more than 500 scientific articles, serves on numerous editorial boards, and is Editor-in-Chief of Urology Case Reports and editor of the Campbell-Walsh urology text. He has been honored with many awards, including the Hopkins Young Investigators Award, the Pfizer Scholars in Urology Award in 1996, and the “Gold-Cystoscope” award in 2001. In 2004, Dr. Partin was named Director of the Department of Urology at the James Buchanan Brady Urological Institute and Urologist-in-Chief of Johns Hopkins Hospital. Dr. Partin is an expert in assessing prognosis and making predictions for men with prostate cancer. The creation of The Partin Tables, which can predict with 95 percent accuracy a man’s likelihood of being cured by treatment, made his research famous. Dr. Partin’s laboratories focus on developing and testing new and existing methods for predicting the aggressiveness of prostate cancers so that rational treatment decisions can be made by both patients and physicians. Dr. Partin’s laboratories have investigated many new “PSA-like” serum tests, some of which are soon to become available for the diagnosis of prostate cancer as well as basic science investigation of new proteins—which may help in detection—and staging of prostate cancer. In addition, Dr. Partin has an academic and clinical interest in the treatment of benign prostatic hyperplasia with an emphasis on minimally invasive techniques. Dr. Partin received his undergraduate degree in Chemistry from the University of Mississippi, where he was an Academic All-American football player. He received his medical degree and his PhD in Pharmacology and Molecular Sciences from Johns Hopkins University, where he continued his postdoctoral training.

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

Ask the Expert: Which Non-Genomic Biomarkers Are Most Useful for Monitoring Patients After Initial Treatment?

About The Author

Alan W. Partin, MD, PhD

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

Exercise & Wellness

Ask the Expert: Which Non-Genomic Biomarkers Are Most Useful for Monitoring Patients After Initial Treatment?

About The Author

Alan W. Partin, MD, PhD

Related Posts

The Role of Targeting DNA Repair with PARP

Short Course: Prostate Cancer Prevention, Screening, and Biomarkers

Biomarkers: PSA, 4K, or PHI?

When to Biopsy: The Role for PSA and Novel Biomarkers

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard – Your Courses

Recent Updates

Exercise & Wellness

– Account Dashboard
– Your Courses